Investigation of the effect of pamidronate disodium on the in vitro viability of osteosarcoma cells from dogs
- PMID: 15934617
- DOI: 10.2460/ajvr.2005.66.885
Investigation of the effect of pamidronate disodium on the in vitro viability of osteosarcoma cells from dogs
Abstract
Objective: To determine the effect of pamidronate disodium on the in vitro viability of osteosarcoma cells and non-neoplastic cells from dogs.
Sample population: 3 osteosarcoma and 1 fibroblast cell lines derived from dogs.
Procedure: Cell counts and cell viability assays were performed in cultures of osteosarcoma cells (POS, HMPOS, and COS31 cell lines) and fibroblasts after 24, 48, and 72 hours of incubation with pamidronate at concentrations of 0.001 to 1000 microM or with no drug (control treatment). Percentage viability was determined in cell samples for each concentration of pamidronate and each incubation time. A DNA fragmentation analysis was performed to assess bisphosphonate-induced apoptosis.
Results: Osteosarcoma cell viability decreased significantly in a concentration- and time-dependent manner at pamidronate concentrations ranging from 100 to 1000 microM, most consistently after 48 and 72 hours' exposure. In treated osteosarcoma cells, the lowest percentage cell viability was 34% (detected after 72 hours' exposure to 1000 microM pamidronate). Conversely, 72 hours' exposure to 1000 microM pamidronate did not significantly reduce fibroblast viability (the lowest percentage viability was 76%). After 72 hours of exposure, pamidronate did not cause DNA fragmentation in POS or HMPOS cells.
Conclusions and clinical relevance: Results indicate that pamidronate may have the potential to inhibit osteosarcoma growth in dogs, possibly through a nonapoptotic mechanism. The clinical relevance of these in vitro findings remains to be determined, but administration of pamidronate may potentially be indicated as an adjuvant treatment in chemotherapeutic protocols used in dogs.
Similar articles
-
Investigation of the effects of deracoxib and piroxicam on the in vitro viability of osteosarcoma cells from dogs.Am J Vet Res. 2005 Nov;66(11):1961-7. doi: 10.2460/ajvr.2005.66.1961. Am J Vet Res. 2005. PMID: 16334957
-
The effect of the bisphosphonate alendronate on viability of canine osteosarcoma cells in vitro.In Vitro Cell Dev Biol Anim. 2004 Mar-Apr;40(3-4):113-7. doi: 10.1290/1543-706x(2004)040<0113:teotba>2.0.co;2. In Vitro Cell Dev Biol Anim. 2004. PMID: 15311969
-
Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro.Am J Vet Res. 2010 Jul;71(7):799-808. doi: 10.2460/ajvr.71.7.799. Am J Vet Res. 2010. PMID: 20594083
-
The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro.Anticancer Drugs. 2001 Jun;12(5):459-65. doi: 10.1097/00001813-200106000-00007. Anticancer Drugs. 2001. PMID: 11395574
-
Biological activity of dihydroartemisinin in canine osteosarcoma cell lines.Am J Vet Res. 2008 Apr;69(4):519-26. doi: 10.2460/ajvr.69.4.519. Am J Vet Res. 2008. PMID: 18380584
Cited by
-
Strategies for the targeted delivery of therapeutics for osteosarcoma.Expert Opin Drug Deliv. 2009 Dec;6(12):1311-21. doi: 10.1517/17425240903280422. Expert Opin Drug Deliv. 2009. PMID: 19761419 Free PMC article. Review.
-
Addition of pamidronate to chemotherapy for the treatment of osteosarcoma.Cancer. 2011 Apr 15;117(8):1736-44. doi: 10.1002/cncr.25744. Epub 2010 Nov 8. Cancer. 2011. PMID: 21472721 Free PMC article. Clinical Trial.
-
Dog breeds and body conformations with predisposition to osteosarcoma in the UK: a case-control study.Canine Med Genet. 2021 Mar 10;8(1):2. doi: 10.1186/s40575-021-00100-7. Canine Med Genet. 2021. PMID: 33750475 Free PMC article.
-
Skeletal imaging effects of pamidronate therapy in osteosarcoma patients.Pediatr Radiol. 2011 Apr;41(4):451-8. doi: 10.1007/s00247-010-1883-4. Epub 2010 Oct 30. Pediatr Radiol. 2011. PMID: 21052656
-
Pamidronate disodium for palliative therapy of feline bone-invasive tumors.Vet Med Int. 2014;2014:675172. doi: 10.1155/2014/675172. Epub 2014 Jun 9. Vet Med Int. 2014. PMID: 25013741 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources